In This Section

Program

Please note that this meeting will take place as an in-person event in Los Angeles and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

[R] – Remote Presentation

Thursday, March 5

Friday, March 6

Saturday, March 7

SUNday, March 8

Thursday, March 5

REGISTRATION

3-7 p.m. | Diamond 1-4 Foyer 

WELCOME AND Keynote lectures

6-7:30 p.m. | Diamond 5 

  • 6 p.m. | Drugging RAS: What a long, strange trip it’s been  
    Channing Der, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
  • 6:45 p.m. | Rising Star Keynote
    Response and resistance to RAS blockade in solid tumors and beyond
    Sandra Misale, Johns Hopkins University, Baltimore, Maryland

Opening Reception

7:30-9 p.m. | Diamond 1-3

Friday, March 6

CONTINENTAL BREAKFAST AND NETWORKING ROUNDTABLES

7-8 a.m. | Diamond 1-3

Plenary Session 1: RAS Biochemistry, Structure, and Mutations

8-10 a.m. | Diamond 5 

  • 8:05 a.m. | Piro Lito, Memorial Sloan Kettering Cancer Center, New York, New York
  • 8:35 a.m. | Mark Philips, New York University Perlmutter Cancer Center, New York, New York
  • 9:05 a.m. | Identification of a RAS-GTP Threshold for Malignant Transformation* 
    Sophie Krahnke, Frederick National Laboratory, Frederick, MD
  • 9:15 a.m. | Targeting S6K2 overcomes resistance to RAS inhibition in NRAS-mutant melanoma*
    Jessie Villanueva, The Wistar Institute, Philadelphia, PA

Short talks selected from proffered abstracts

BREAK

10-10:15 a.m. | Diamond 1-4 Foyer

Plenary Session 2: Effector Signaling

10:15 a.m.-12:15 p.m. | Diamond 5 

  • 10:20 a.m. | Determinants of KRAS effector signalling in pancreatic cancer – from tumor evolution to tumor-host interactions
    Dieter Saur, German Cancer Research Center and Technical University of Munich, Munich, Germany
  • 10:50 a.m. | Targeting the SHOC2-RAS interaction in RAS-mutant cancers
    Zachary Hauseman, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 
  • 11:20 a.m. | MEK1/2 degraders uncover kinase-independent role of MEK1/2 in CRAF stabilization and maturation*
    James Duncan, Fox Chase Cancer Center, Philadelphia, PA
  • 11:30 a.m. | Dissecting the critical ERK functions that support KRAS-driven pancreatic cancer*
    Jennifer Klomp, Michigan State University, Grand Rapids, MI 

Short talks selected from proffered abstracts

Lunch on Own

12:15-2:15 p.m.

Plenary Session 3: Colorectal Cancer: Therapeutic Challenges and Opportunities

2:15-4:15 p.m. | Diamond 5 

  • 2:20 p.m. | Rona Yaeger, Memorial Sloan Kettering Cancer Center, New York, New York
  • 2:50 p.m | Ryan Corcoran, Massachusetts General Hospital, Boston, Massachusetts  
  • 3:20 p.m. | Ignacio Garrido-Laguna, Huntsman Cancer Center, University of Utah, Salt Lake City, UT 

break

4:30-4:45 p.m. | Diamond 1-4 Foyer

Plenary session 4: RAS omics and Early Detection Advances

4:45-6:30 p.m. | Diamond 5 

  • 4:50 p.m. | Laura Wood, Johns Hopkins University, Baltimore, Maryland
  • 5:20 p.m. | Oncogenic Kras as a driver of the pancreatic cancer microenvironment
    Marina Pasca di Magliano, University of Michigan, Ann Arbor, Michigan
  • 5:50 p.m. | KRAS amplification as de novo oncogenic alteration and therapeutic target in human cancers*
    Mark Awad, Memorial Sloan Kettering Cancer Center, New York, NY 
  • 6:00 p.m. | Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activity
    Jason Kwon, Dana-Farber Cancer Institute, Boston, MA

Short talks selected from proffered abstracts

Poster Session A and Reception

6:45-8:45 p.m. | Diamond 4

Saturday, March 7

CONTINENTAL BREAKFAST AND Networking Roundtables           

7-8 a.m. | Diamond 1-3

Keynote Lecture

8-8:45 a.m. | Diamond 5 

  • 8 a.m. | Targeting the oncogenic state of RAS: Lessons from tri-complex inhibitors
    Mallika Singh, Revolution Medicines, Redwood City, California

Plenary Session 5: RAS Clinical Trials and New Therapies

8:45-10:45 a.m. | Diamond 5 

  • 8:50 a.m. | Ferdinandos Skoulidis, UT MD Anderson Cancer Center, Houston, Texas
  • 9:20 a.m. | Eileen O’Reilly, Memorial Sloan Kettering Cancer Center, New York, New York
  • 9:50 a.m. | Anti-tumor efficacy of the selective oral KRAS G12D dual ON/OFF inhibitor VS-7375 as a single agent and in combination with targeted agents*
    Jonathan Pachter, Verastem Oncology, Needham, MA 
  • 10:00 a.m. | Preclinical activity of an orally bioavailable PROTAC pan-KRAS degrader versus inhibitors in mutant KRAS models*
    Andrea Lopez-Arroyo, Arnivas Operations Inc, New Haven, CT 

Break

10:45-11 a.m. | Diamond 1-4 Foyer

Plenary Session 6: Combinations

11 a.m.-1:30 p.m. | Diamond 5 

  • 11:05 a.m. | Targeting KRAS driven pancreatic cancer: Combination therapies   
    Mariano Barbacid, Spanish National Cancer Research Center (CNIO), Madrid, Spain 
  • 11:35 a.m. | Karen Cichowski, Brigham and Women’s Hospital, Boston, Massachusetts
  • 12:05 p.m. | David Tuveson, Cold Spring Harbor Laboratory, New York, New York
  • 12:35 p.m. | The RAS(ON) multi-selective inhibitor, daraxonrasib (RMC-6236), induces Receptor Tyrosine Kinase (RTK) cell surface expression on pancreatic cancer cells, providing rationale for combinations with RTK targeting agents* 
    Ida Aronchik, Revolution Medicines, Redwood City, CA

Short talks selected from proffered abstracts

Lunch on Own

1:30-3:15 p.m.

Plenary Session 7: Immunobiology and Immunotherapies for RAS Malignancies

3:15-5:45 p.m. | Diamond 5 

  • 3:20 p.m. | Philip Greenberg, Fred Hutchinson Cancer Center, Seattle, Washington
  • 3:50 p.m. | Mutant KRAS-Targeted Vaccines for Cancer Treatment and Interception
    Elizabeth Jaffee, Johns Hopkins University School of Medicine, Baltimore, Maryland
  • 4:20 p.m. | Ron DePinho, MD Anderson Cancer Center, Houston, Texas
  • 4:50 p.m. | KRAS amplification creates a targetable pMHC antigen for T cell engager therapy to overcome KRAS inhibitor resistance*
    Lauren Stopfer, Aethon Therapeutics, New York, NY
  • 5:00 p.m. | Kras G12C and G12D driven lung cancers differ in oncogenic potency, immunogenicity, and relapse following Kras inhibition* 
    Esra A. Akbay, University of Texas Southwestern Medical Center, Dallas, TX 

Short talks selected from proffered abstracts

Break

5:45-6 p.m. | Diamond 1-4 Foyer

Special Session from the NCI RAS Initiative

6-7:30 p.m. | Diamond 5 

Poster Session B and Reception

7:30-9:30 p.m. | Diamond 4

Sunday, March 8

Continental Breakfast and Networking Roundtables

7-8 a.m.

Plenary Session 8: Resistance Mechanisms

8-10 a.m. | Diamond 5 

  • 8:05 a.m. | Signaling plasticity in pre-clinical models of resistance to KRAS inhibitors
    Chiara Ambrogio, Molecular Biotechnology Center (MBC), University of Torino, Torino, Italy
  • 8:35 a.m. | Boosting the immune system to counter resistance to KRAS inhibitory drugs in lung cancer 
    Julian Downward, The Francis Crick Institute, London, United Kingdom
  • 9:05 a.m. | Dynamic kinome reprogramming and metabolic rewiring drive adaptive resistance to RAS inhibition in pancreatic cancer* 
    Clint A. Stalnecker, University of North Carolina at Chapel Hill, Chapel Hill, NC 
  • 9:15 a.m. | A PP2A molecular glue overcomes RAS/MAPK inhibitor resistance in KRAS-mutant non–small cell lung cancer*
    Goutham Narla, The University of Michigan, Ann Arbor, MI 

Short talks selected from proffered abstracts

Break

10-10:15 a.m. | Diamond 1-4 Foyer

Plenary Session 9: Targeting NRAS, HRAS, and Rare KRAS Subtypes

10:15 a.m.-12:45 p.m. | Diamond 5 

  • 10:20 a.m. | Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi- Selective Inhibitors in NRAS-Mutated Melanoma
    Martin McMahon, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah
  • 10:50 a.m. | Targeting the Palmitoylation Cycle in NRAS-Mutant Cancers
    Kevin Shannon, University of California, San Francisco, San Francisco, California
  • 11:20 a.m. | Factors regulating permissively of organs to oncogenic RAS
    Kevin Haigis, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 11:50 a.m. | Silent KRAS mutations confer altered sensitivity to targeted KRAS inhibition*
    Andrew  M. Waters, University of Cincinnati, Cincinnati, OH 
  • 12:00 p.m. | De novo design of Ras isoform selective binders*
    Jason Z.  Zhang, UCLA, Los Angeles, CA 

Short talks selected from proffered abstracts

Closing Remarks

12:45 p.m. | Diamond 5